Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicago, a biotechnology company, has completed initial studies towards the development of a new VLP vaccine candidate for rabies.
Subscribe to our email newsletter
The initial studies with rabies VLP vaccine demonstrated that two doses of one or four micrograms induced protective levels of neutralizing antibodies in a mouse model.
The company expects to move ahead with GMP process development and a GLP toxicology study in 2012 and a Phase I clinical trial.
Medicago president and CEO Andrew Sheldon said that they see significant potential for our technologies in the development of VLP vaccines and biosimilars.
"The rabies virus is a significant problem where current vaccines present challenges to access due to availability and cost, which we believe our VLP vaccine could address," Sheldon added.